Blood Tests for Alzheimer's: Promise, Limits, and What to Ask

Yes — for the first time, there is an FDA-cleared blood test to help diagnose Alzheimer's disease, and it's a genuine milestone, with genuine limits. In May 2025 the FDA cleared a plasma test that measures a ratio of brain proteins to help detect Alzheimer's-related changes in people already experiencing cognitive symptoms. It can spare many patients an invasive spinal tap or an expensive brain scan. What it is not is a screening test for healthy people who simply want to know their future — and understanding that distinction is the difference between using this breakthrough well and misreading it.

What did the FDA actually approve?

On May 16, 2025, the FDA cleared the first blood test for diagnosing Alzheimer's: a plasma assay reporting the ratio of two proteins — p-tau217 and beta-amyloid 1-42. Both are tied to the underlying biology of Alzheimer's, and measured together as a ratio they reliably indicate whether the amyloid plaques characteristic of the disease are likely present. The clearance is specifically for symptomatic adults aged 55 and older who are being evaluated for the disease.

Why this is a milestone: until now, confirming Alzheimer's pathology meant either a PET scan (costly, not always accessible) or a lumbar puncture (invasive). A blood test is cheaper, faster, and far less burdensome — which means earlier, wider access to an accurate answer for people who need one.

How accurate is it?

Reassuringly accurate for what it's designed to do. In people with cognitive impairment, plasma p-tau217-based testing has shown accuracy in the range of around 90% for detecting Alzheimer's pathology, with performance clinically comparable to the established PET and spinal-fluid tests it can replace. That's a high bar, and it's why the field has moved so quickly: a blood draw is now, in the right patient, about as informative as procedures that are far more invasive and expensive.

Two honest caveats sit alongside that number. First, "around 90%" is excellent but not perfect — results inform a diagnosis, they don't deliver one by themselves. Second, that accuracy has been established in people with symptoms. It does not automatically transfer to healthy people with no cognitive complaints, which is the crucial limit.

Who is the test actually for?

This is the part most worth understanding. The test is cleared and recommended for people who already have cognitive symptoms and are being evaluated for their cause — not for screening the healthy and worried-well.

The reason is both scientific and humane. In symptomatic patients, a positive result helps explain what's happening and guides care. In a healthy person with no symptoms, the same result is far harder to interpret: Alzheimer's pathology can be present in the brain for years or decades before any symptoms appear — and may, in some people, never produce them in their lifetime. Telling a symptom-free person they have amyloid in their brain, with no approved way to act on it and no certainty it will ever cause problems, can cause real harm without clear benefit. Researchers are actively studying whether these tests could one day screen asymptomatic people — but that day depends on having effective preventive treatments to offer, which we don't yet have at scale.

This is why professional bodies have moved carefully. The Alzheimer's Association has issued appropriate-use guidance and clinical practice recommendations to help specialists decide who should be tested and when, precisely so a powerful tool is used where it helps and not where it merely frightens.

What a blood test can't do

To hold the promise and the limits together honestly:

• It doesn't diagnose Alzheimer's by itself. It detects the presence of disease-related pathology and supports a clinical diagnosis made by a doctor who also considers symptoms, history, and other assessments.
• It isn't a crystal ball for the healthy. A positive result in someone without symptoms doesn't reliably predict if or when dementia will develop.
• It doesn't yet change what's treatable. Knowing earlier matters for planning, for ruling causes in or out, and increasingly for access to emerging therapies — but the test is a diagnostic aid, not a cure or a prevention.
• It's a confirmatory and triage aid, not a consumer screening kit. Its value is realized inside a proper clinical evaluation.

What should you ask your doctor?

If memory or thinking changes have brought you or a loved one to this question, a few questions help you use this advance well:

• Are my symptoms significant enough to warrant testing for Alzheimer's pathology?
• Would a blood biomarker test add useful information in my specific case, or should we start with other assessments?
• If the result is positive, how would it change my care or options? If negative, what would we look at next?
• Could something else — sleep, medication, mood, thyroid, vitamin levels — be contributing, and have we ruled those out?

That last question matters, because many causes of memory trouble are treatable and reversible, and a good evaluation looks for those first. (For where this fits, see What Really Happens to Memory as We Age.)

The arrival of an accurate, less invasive blood test is one of the most hopeful developments in Alzheimer's diagnosis in decades. Used as intended — to help people with symptoms get clearer, earlier answers — it's a real gift. The promise is best protected by being honest about the limits: this is a tool to bring clarity to those who need it, not certainty to those who don't.

Frequently asked questions

Is there a blood test for Alzheimer's disease? Yes. In May 2025 the FDA cleared the first blood test to help diagnose Alzheimer's — a plasma test measuring a p-tau217/beta-amyloid ratio — for use in adults aged 55 and older who already have cognitive symptoms and are being evaluated for the disease.

How accurate is the Alzheimer's blood test? In people with cognitive symptoms, p-tau217-based blood testing has shown accuracy around 90% for detecting Alzheimer's pathology, clinically comparable to PET scans and spinal-fluid tests. It still supports a diagnosis rather than making one on its own.

Can a healthy person get an Alzheimer's blood test to predict their risk? It isn't recommended for screening people without symptoms. Alzheimer's pathology can exist for years without causing symptoms, so a positive result in a healthy person is hard to interpret and can cause harm without clear benefit. The test is intended for symptomatic patients in specialty care.

Brain Meets Bytes — Science First. Human Always. Subscribe for clear, evidence-based brain-health insight.

This article is for general education and is not medical advice. Decisions about diagnostic testing should be made with a qualified healthcare professional.